Assembly Biosciences, Inc. Restructuring and Related Cost, Cost Incurred to Date
Assembly Biosciences, Inc. (ASMB) had Restructuring and Related Cost, Cost Incurred to Date of $6.43 million as of 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Notes › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2022-03-11
- 2021-12-31: Restructuring and Related Cost, Cost Incurred to Date $6.43M.
- 2021-09-30: Restructuring and Related Cost, Cost Incurred to Date $6.43M.
- 2021-06-30: Restructuring and Related Cost, Cost Incurred to Date $6.43M.
- 2021-03-31: Restructuring and Related Cost, Cost Incurred to Date $6.73M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2021-12-31 | $6.43M 10-K · filed 2022-03-11 |
| 2021-09-30 | $6.43M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $6.43M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.73M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $7.78M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |